SCHEMBL6893587

SCHEMBL6893587

Nc1c(Br)c(N2CCC(CC(=O)O)C2)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.40
FGFR2 P21802 5/20 0.40
PDE2A O00408 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OGFRL1 Q5TC84 1/20 0.38
FAAH O00519 1/20 0.37
PIK3CA P42336 3/20 0.36
CHEK1 O14757 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
AKT1 P31749 2/20 0.35
MTOR P42345 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893193 0.95 PDE4B (0.40) EGFRFGFR2OPRM1OPRD1OPRK1
SCHEMBL6893491 0.89 EGFR (0.39) EGFRFGFR2FAAHPIK3CACHEK1
SCHEMBL594021 0.88 EGFR (0.41) EGFRFGFR2PDE2AOGFRL1PIK3CA
SCHEMBL6891513 0.86 FGFR2 (0.37) EGFRFGFR2FAAHPIK3CACHEK1
SCHEMBL6894483 0.84 EGFR (0.40) EGFRFGFR2PDE2AOPRM1OPRD1
SCHEMBL10234073 0.84 FGFR2 (0.41) EGFRFGFR2PIK3CACHEK1CCNA2
SCHEMBL2680298 0.83 EGFR (0.40) EGFRFGFR2PIK3CAMTORKDM4E
SCHEMBL7881471 0.83 AKT1 (0.43) EGFRFGFR2PIK3CACHEK1CCNA2
SCHEMBL2679709 0.83 CHEK1 (0.44) EGFRFGFR2PIK3CACHEK1CCNA2
SCHEMBL2680297 0.83 CHEK1 (0.44) EGFRFGFR2PIK3CACHEK1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
WO-2010118207-A1 PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 EGFR 4536/4885FGFR2 3710/4885PDE2A 2733/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR EGFR 2799/4885FGFR2 1827/4885PDE2A 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.